GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Range Low Price High Price Comment
30 days $4.45 $5.86 Thursday, 18th Apr 2024 BCRX stock ended at $4.50. This is 1.75% less than the trading day before Wednesday, 17th Apr 2024. During the day the stock fluctuated 4.90% from a day low at $4.49 to a day high of $4.71.
90 days $4.45 $6.35
52 weeks $4.45 $9.07

Historical BioCryst Pharmaceuticals prices

Date Open High Low Close Volume
2024-03-13 $5.14 $5.26 $5.07 $5.14 2 563 478
2024-03-12 $5.31 $5.31 $5.04 $5.14 3 063 016
2024-03-11 $5.47 $5.58 $5.31 $5.32 2 624 338
2024-03-08 $5.27 $5.56 $5.23 $5.43 2 586 222
2024-03-07 $5.25 $5.25 $5.13 $5.18 2 136 518
2024-03-06 $5.45 $5.53 $5.16 $5.21 3 979 894
2024-03-05 $5.47 $5.50 $5.31 $5.41 1 896 498
2024-03-04 $5.62 $5.68 $5.41 $5.51 2 158 355
2024-03-01 $5.67 $5.89 $5.61 $5.62 2 931 802
2024-02-29 $5.85 $5.93 $5.60 $5.63 3 354 913
2024-02-28 $5.77 $6.02 $5.69 $5.71 3 333 570
2024-02-27 $5.89 $6.04 $5.65 $5.87 3 559 737
2024-02-26 $5.70 $6.03 $5.64 $5.79 4 000 390
2024-02-23 $5.81 $5.87 $5.61 $5.71 2 686 811
2024-02-22 $5.65 $5.89 $5.54 $5.82 1 778 350
2024-02-21 $5.76 $5.78 $5.54 $5.65 1 858 532
2024-02-20 $5.75 $5.95 $5.71 $5.82 2 121 879
2024-02-16 $5.55 $5.98 $5.49 $5.92 2 608 590
2024-02-15 $5.63 $5.88 $5.53 $5.64 3 682 924
2024-02-14 $5.37 $5.59 $5.20 $5.57 4 163 292
2024-02-13 $5.69 $5.71 $5.31 $5.32 3 533 200
2024-02-12 $5.89 $6.35 $5.87 $5.95 5 190 185
2024-02-09 $5.39 $5.87 $5.32 $5.85 4 391 855
2024-02-08 $5.29 $5.38 $5.16 $5.32 1 811 314
2024-02-07 $5.50 $5.54 $5.29 $5.30 2 552 807
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT